Triokris™ (Trientine Hydrochloride Capsules USP 250 mg)
Trusted Therapy for Wilson’s Disease Management
Triokris™ is a chelating agent indicated for the treatment of Wilson’s Disease, particularly in patients who cannot tolerate D-Penicillamine. Manufactured
in a USFDA-approved facility and distributed by Ikris Pharma Network, Triokris™ ensures global-standard safety, efficacy, and compliance.
About Wilson’s Disease:
Wilson’s disease is a rare genetic disorder of copper metabolism that leads to toxic accumulation of copper in the liver, brain, and other vital organs.
Early diagnosis and lifelong treatment are essential to prevent severe complications.
Trientine Hydrochloride (Triokris™) is a key therapy recommended when D-Penicillamine is not tolerated, offering patients a reliable and safer alternative.
Clinical Benefits of Triokris™ :-
Effective in hepatic & neurological manifestations of Wilson’s Disease.
Lower risk of hypersensitivity compared to D-Penicillamine.
Improves long-term clinical outcomes with continuous therapy.
Well tolerated by patients requiring lifelong copper management.
Dosage & Administration:-
Adults & Adolescents: Usual dose ranges between 750–1500 mg/day, divided into 2–4 doses.
Must be taken on an empty stomach (at least 1 hour before or 2 hours after meals).
Should not be taken with iron, zinc, calcium, or magnesium supplements at the same time, as they interfere with absorption.
Dosage must be individualized and supervised by a physician based on patient needs and monitoring results.
Safety & Precautions:-
Not interchangeable with D-Penicillamine.
Contraindicated in patients with known hypersensitivity to Trientine.
Regular monitoring required: liver function tests, blood counts, serum copper, and ceruloplasmin levels.
Caution advised: may cause anaemia due to iron depletion—patients should be monitored closely.
Product Information:-
Active Ingredient: Trientine Hydrochloride USP
Strength: 250 mg capsules
Presentation: 100 capsules per bottle
Storage: Store at 25°C, protected from moisture and light.
Manufacturing: Produced in a USFDA-approved facility ensuring global safety and quality standards.
Why Choose Triokris™ from Ikris Pharma Network?:-
Manufactured in a USFDA-approved facility.
Supplied through EU-GDP, WHO-GDP & ISO-certified logistics.
Global access in India, Africa, Asia, Middle East, and Latin America.
Reliable partner for Named Patient Programs & compliant supply chains.
Frequently Asked Questions (FAQs):
What is Triokris (Trientine Hydrochloride Capsules) used for?
Triokris™ (Trientine Hydrochloride Capsules USP 250 mg) is used in the treatment of Wilson’s Disease, a rare disorder where excess copper builds up in the body. It is especially recommended for patients who cannot tolerate D-Penicillamine.
How does Trientine work in Wilson’s Disease?
Trientine acts as a chelating agent, meaning it binds to excess copper in the body and helps remove it through urine. This reduces copper accumulation in the liver, brain, and other organs, preventing long-term damage.
Is Triokris available in India?
Yes. Triokris™ is available in India through Ikris Pharma Network, manufactured in a USFDA-approved facility and supplied via WHO-GDP & ISO-certified logistics.
What is the usual dosage of Trientine?
For adults and adolescents, the typical dose ranges from 750–1500 mg/day, divided into 2–4 doses. It must be taken on an empty stomach and only under physician supervision.
What precautions should patients take while using Trientine?
* Not interchangeable with D-Penicillamine.
* Avoid taking at the same time as iron, zinc, calcium, or magnesium supplements.
* Regular monitoring of liver function, blood counts, and copper levels is essential.
Can Triokris be exported to other countries?
Yes. Through Ikris Pharma Network’s global distribution channels, Triokris™ can be exported to Africa, Asia, Middle East, Europe, and Latin America under compliant supply programs and Named Patient Programs where required.
References:
Ferenci P, Członkowska A. Trientine for Wilson’s Disease: A review of clinical outcomes. Clin Liver Dis (Hoboken). 2023.
Weiss KH, Stremmel W. Clinical management of Wilson’s Disease with chelating agents: Focus on Trientine.World J Gastroenterol. 2022.
Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: An update. Hepatology. 2008.
American Association for the Study of Liver Diseases (AASLD). Wilson Disease Clinical Practice Guidelines.2022.
Członkowska A, Litwin T, Dusek P, et al. Wilson disease – A comprehensive review of pathophysiology, clinical presentation, and management. Orphanet J Rare Dis. 2018.
Mayo Clinic. Wilson’s Disease – Symptoms and causes. 2023.
